Opening book details…
Can I read Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study on EtoBox?
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study by Cataldo Patruno; Gabriella Fabbrocini; Giuseppe Longo; Giuseppe Argenziano; Silvia Mariel Ferrucci; Luca Stingeni; Ketty Peris; Michela Ortoncelli; Annamaria Offidani; Giuseppe Fabrizio Amoruso; Marina Talamonti; Giampiero Girolomoni; Teresa Grieco; Michela Iannone; Eustachio Nettis; Caterina Foti; Franco Rongioletti; Monica Corazza; Michele Delli Veneri; Maddalena Napolitano; L Angileri; T Bianchelli; A Borghi; G Calabrese; C Chello; G Dal Bello; S Dastoli; M Ferrillo; M Galluzzo; N Gori; K Hansel; L Macchia; V Piras; E Provenzano; S Ribero; M Romanelli; P Romita; Dupilumab for Atopic Dermatitis of the Elderly (DADE) Study Group is a Medicine article available to read on EtoBox.
What is Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study about?
## Objective: The objective of this study was to assess the effectiveness and safety of dupilumab in treating elderly patients with atopic dermatitis from baseline to 52 weeks. ## Methods: A retrospective observational real-life study was conducted in a group of elderly patients with severe atopic dermatitis treated with dupilumab for 52 weeks. inclusion criteria were: age ≥ 65 years; diagnosis of atopic dermatitis made by an expert dermatologist; eczema area and severity index ≥ 24; and a contraindication, side effects, or failure to respond to cyclosporine. the primary outcome was the mean percentage reduction in the eczema area and severity index score from baseline to week 52. secondary measures included the mean percentage reduction in the pruritus and sleep numerical rating scales and the dermatology life quality index, and the types and rates of adverse events from baseline to week 52. ## Results: One hundred and five patients were eligible for the study. flexural dermatitis was the most frequent clinical phenotype (63.8%). the coexistence of more than one clinical phenotype was found in 70/105 (66.6%) patients. we observed a reduction in all disease severity scores from bas
Who reads Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Cataldo Patruno; Gabriella Fabbrocini; Giuseppe Longo; Giuseppe Argenziano; Silvia Mariel Ferrucci; Luca Stingeni; Ketty Peris; Michela Ortoncelli; Annamaria Offidani; Giuseppe Fabrizio Amoruso; Marina Talamonti; Giampiero Girolomoni; Teresa Grieco; Michela Iannone; Eustachio Nettis; Caterina Foti; Franco Rongioletti; Monica Corazza; Michele Delli Veneri; Maddalena Napolitano; L Angileri; T Bianchelli; A Borghi; G Calabrese; C Chello; G Dal Bello; S Dastoli; M Ferrillo; M Galluzzo; N Gori; K Hansel; L Macchia; V Piras; E Provenzano; S Ribero; M Romanelli; P Romita; Dupilumab for Atopic Dermatitis of the Elderly (DADE) Study Group
- Publisher
- Springer Science and Business Media LLC
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)